Patents by Inventor Marian Braendle

Marian Braendle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and ?-cell dysfunction
    Patent number: 10292949
    Abstract: The invention relates to a pharmaceutical composition comprising as active ingredient an effective amount of 2-Methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the prophylaxis and therapy of Type II diabetes mellitus, the Metabolic syndrome, diabetic nephropathy and/or neuropathy. Another object of the invention concerns the use of 2-Methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the enhancement of insulin sensitivity and the preservation or increase of ß-cell compensation.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: May 21, 2019
    Assignee: Meck Patent GmbH
    Inventors: Norbert Beier, Wolfgang Scholz, Ulrich Betz, Marian Braendle
  • PHARMACEUTICAL COMPOSITION COMPRISING RIMEPORIDE FOR TREATING DISEASES ASSOCIATED WITH INSULIN RESISTANCE AND BETA-CELL DYSFUNCTION
    Publication number: 20170189354
    Abstract: The invention relates to a pharmaceutical composition comprising as active ingredient an effective amount of 2-Methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the prophylaxis and therapy of Type II diabetes mellitus, the Metabolic syndrome, diabetic nephropathy and/or neuropathy. Another object of the invention concerns the use of 2-Methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the enhancement of insulin sensitivity and the preservation or increase of ?-cell compensation.
    Type: Application
    Filed: March 24, 2017
    Publication date: July 6, 2017
    Applicant: Merck Patent GmbH
    Inventors: Norbert BEIER, Wolfgang SCHOLZ, Ulrich BETZ, Marian BRAENDLE
  • PHARMACEUTICAL COMPOSITION COMPRISING RIMEPORIDE FOR TREATING DISEASES ASSOCIATED WITH INSULIN RESISTANCE AND BETA-CELL DYSFUNCTION
    Publication number: 20110060051
    Abstract: The invention relates to a pharmaceutical composition comprising as active ingredient an effective amount of 2-Methyl-4,5-di-(methylsulfonyI)-benzoyl-guanidine, or derivatives thereof, for the prophylaxis and therapy of Type II diabetes mellitus, the Metabolic syndrome, diabetic nephropathy and/or neuropathy. Another object of the invention concerns the use of 2-Methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the enhancement of insulin sensitivity and the preservation or increase of ?-cell compensation.
    Type: Application
    Filed: April 11, 2009
    Publication date: March 10, 2011
    Applicant: Merck Patent Gesellschaft Mit Beschrankter Haftung
    Inventors: Norbert Beier, Wolfgang Scholz, Ulrich Betz, Marian Braendle
  • USE OF CARP INHIBITORS FOR THE TREATMENT OF HEART DISEASES
    Publication number: 20070293579
    Abstract: The present invention relates to the novel finding that inhibition of human CARP protein or of CARP DNA/mRNA may successfully cure heart disorders, especially heart failure in humans. The invention relates, therefore, to pharmaceutical compositions containing substances, preferably of lower molecular weight, which may influence the activity of cardiac CARP. The invention relates, furthermore, to a method of treatment heart failure using CARP inhibitory compounds, to methods for screening these inhibitors and to the use of CARP as diagnostic tool.
    Type: Application
    Filed: February 20, 2007
    Publication date: December 20, 2007
    Inventors: Franz-Werner Kluxen, Bernd Hentsch, Claudia Wilm, Marian Braendle, Thomas Ehring, Thomas Eschenghagen, Oliver Zolk
  • Use of carp inhibitors for the treatment of heart diseases
    Publication number: 20040014706
    Abstract: The present invention relates to the novel finding that inhibition of human CARP protein or of CARP DNA/mRNA may successfully cure heart disorders, especially heart failure in humans. The invention relates, therefore, to pharmaceutical compositions containing substances, preferably of lower molecular weight, which may influence the activity of cardiac CARP. The invention relates, furthermore, to a method of treatment heart failure using CARP inhibitory compounds, to methods for screening these inhibitors and to the use of CARP as diagnostic tool.
    Type: Application
    Filed: August 7, 2003
    Publication date: January 22, 2004
    Inventors: Franz-Werner Kluxen, Bernd Hentsch, Claudia Wilm, Marian Braendle, Thomas Eschenhagen, Thomas Eschenhagen, Oliver Zolk